SEC Company Response from Avidity Biosciences, Inc. (RNA) (CIK 0001599901) (RNA) — Jun 9, 2020
Avidity Biosciences, Inc. (RNA) (CIK 0001599901)
Date: June 9, 2020 · CIK: 0001599901 · Accession: 0001193125-20-164621
AI Filing Summary & Sentiment
File numbers found in text: 333-238612
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Washington, D.C. 20549 Re: Avidity Biosciences, Inc. Registration Statement on Form S-1 File No. 333-238612
Dear Ms. Sarmento:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Avidity Biosciences, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 11, 2020, or as soon as practicable thereafter.
Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
Very truly yours,
AVIDITY BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Avidity Biosciences, Inc. 10975 N. Torrey Pines Road, Suite 150 La Jolla, California 92037 June 9, 2020 VIA EDGAR Ms. Ada D. Sarmento Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Avidity Biosciences, Inc. Registration Statement on Form S-1 File No. 333-238612 Dear Ms. Sarmento: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Avidity Biosciences, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 11, 2020, or as soon as practicable thereafter. Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter. Very truly yours, AVIDITY BIOSCIENCES, INC. By: s/ Sarah Boyce Sarah Boyce President, Chief Executive Officer and Director cc: Mary Mast, Securities and Exchange Commission Mary Beth Breslin, Securities and Exchange Commission Christine Torney, Securities and Exchange Commission Sarah Boyce, Securities and Exchange Commission Michael F. MacLean, Avidity Biosciences, Inc. Cheston J. Larson, Latham & Watkins LLP Matthew T. Bush, Latham & Watkins LLP Alaina P. Ellis, Latham & Watkins LLP